98%
921
2 minutes
20
Obesity can initiate, promote, and maintain systemic inflammation via metabolic reprogramming of macrophages that encircle adipocytes, termed crown-like structures (CLS). In breast cancer the presence of CLS has been correlated to high body mass index (BMI), larger mammary adipocyte size and postmenopausal status. However, the prognostic significance of CLS in HER2 + breast cancer is still unknown. We investigated the prognostic significance of CLS in a cohort of 69 trastuzumab-naïve and 117 adjuvant trastuzumab-treated patients with primary HER2 + breast cancer. Immunohistochemistry of tumour blocks was performed for CLS and correlated to clinical outcomes. CLS were more commonly found at the adipose-tumour border (B-CLS) (64.8% of patients). The presence of multiple B-CLS was associated with reduced time to metastatic disease (TMD) in trastuzumab treated patients with BMI ≥ 25 kg/m but not those with BMI < 25 kg/m. Phenotypic analysis showed the presence of CD32B + B-CLS was strongly correlated to BMI ≥ 25 kg/m and reduced TMD in trastuzumab treated patients. Multivariable analysis suggested that CD32B + B-CLS positive tumours are associated with shorter TMD in trastuzumab-treated patients (HR 4.2 [95%CI, (1.01-17.4). This study indicates adipose-tumour border crown-like structures that are CD32B + potentially represent a biomarker for improved personalisation of treatment in HER2-overexpressed breast cancer patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130517 | PMC |
http://dx.doi.org/10.1038/s41598-022-11696-6 | DOI Listing |
Front Immunol
September 2025
Department of Medicine, Division of Hematology, Bioclinicum and Center for Molecular Medicine, Karolinska Institute and Karolinska University Hospital Solna, Stockholm, Sweden.
Background: Metabolic reprogramming is an important hallmark of cervical cancer (CC), and extensive studies have provided important information for translational and clinical oncology. Here we sought to determine metabolic association with molecular aberrations, telomere maintenance and outcomes in CC.
Methods: RNA sequencing data from TCGA cohort of CC was analyzed for their metabolic gene expression profile and consensus clustering was then performed to classify tumors into different groups/subtypes.
J Hepatocell Carcinoma
September 2025
Department of Liver Disease, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China.
Objective: Anoikis is an anchorage-dependent programmed cell death implicated in multiple pathological processes of cancers; however, the prognostic value of anoikis-related genes (ANRGs) in hepatocellular carcinoma (HCC) remains unclear. Our study aims to develop an ANRGs-based prediction model to improve prognostic assessment in HCC patients.
Methods: The RNA-seq profile was performed to estimate the expression of ANRGs in HCC patients.
Int J Chron Obstruct Pulmon Dis
September 2025
The First Clinical Medical College of Lanzhou University, Lanzhou, People's Republic of China.
Chronic Obstructive Pulmonary Disease (COPD) is a prevalent chronic respiratory disorder characterized by airway inflammation and irreversible airflow limitation. Its marked heterogeneity and complexity pose significant challenges to traditional clinical assessments in terms of prognostic prediction and personalized management. In recent years, the exploration of biomarkers has opened new avenues for the precise evaluation of COPD, particularly through multi-biomarker prediction models and integrative multimodal data strategies, which have substantially improved the accuracy and reliability of prognostic assessments.
View Article and Find Full Text PDFThe morphological patterns of lung adenocarcinoma (LUAD) are recognized for their prognostic significance, with ongoing debate regarding the optimal grading strategy. This study aimed to develop a clinical-grade, fully quantitative, and automated tool for pattern classification/quantification (PATQUANT), to evaluate existing grading strategies, and determine the optimal grading system. PATQUANT was trained on a high-quality dataset, manually annotated by expert pathologists.
View Article and Find Full Text PDFBreast J
September 2025
University of Hawai'i Cancer Center, Honolulu, Hawaii, USA.
The Oncotype DX test is standardly used for patients with early-stage, hormone-receptor-positive, HER2-negative breast cancers to determine the benefit from chemotherapy and the likelihood of distant recurrence. The relationship between Oncotype DX recurrence scores and race/ethnicity is still being studied. This retrospective study aims to evaluate the relationship between Oncotype DX recurrence scores, race/ethnicity, and clinicopathological factors and to support the applicability of the Oncotype DX test for a diverse breast cancer population of Hawaii.
View Article and Find Full Text PDF